Gentian Diagnostics AS
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more
Gentian Diagnostics AS (GENT) - Total Liabilities
Latest total liabilities as of December 2025: Nkr53.58 Million NOK
Based on the latest financial reports, Gentian Diagnostics AS (GENT) has total liabilities worth Nkr53.58 Million NOK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gentian Diagnostics AS - Total Liabilities Trend (2013–2025)
This chart illustrates how Gentian Diagnostics AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gentian Diagnostics AS Competitors by Total Liabilities
The table below lists competitors of Gentian Diagnostics AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Apiam Animal Health Ltd
AU:AHX
|
Australia | AU$134.72 Million |
|
Ju Teng International Holdings Limited
TW:9136
|
Taiwan | NT$4.88 Billion |
|
Tocvan Ventures Corp
OTCQB:TCVNF
|
USA | $2.35 Million |
|
Cerrado Gold Inc
OTCQX:CRDOF
|
USA | $258.80 Million |
|
Saga Communications Inc
NASDAQ:SGA
|
USA | $56.30 Million |
|
Mulpha International Bhd
KLSE:3905
|
Malaysia | RM2.33 Billion |
|
KWG Resources Inc
PINK:KWGBF
|
USA | $38.53 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Gentian Diagnostics AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.10 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gentian Diagnostics AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gentian Diagnostics AS (2013–2025)
The table below shows the annual total liabilities of Gentian Diagnostics AS from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr53.58 Million | +50.45% |
| 2024-12-31 | Nkr35.61 Million | +3.52% |
| 2023-12-31 | Nkr34.40 Million | +2.33% |
| 2022-12-31 | Nkr33.62 Million | -9.19% |
| 2021-12-31 | Nkr37.02 Million | -9.00% |
| 2020-12-31 | Nkr40.69 Million | +114.78% |
| 2019-12-31 | Nkr18.94 Million | +56.47% |
| 2018-12-31 | Nkr12.11 Million | +38.29% |
| 2017-12-31 | Nkr8.75 Million | +18.00% |
| 2016-12-31 | Nkr7.42 Million | +51.53% |
| 2015-12-31 | Nkr4.90 Million | -58.78% |
| 2014-12-31 | Nkr11.88 Million | -5.36% |
| 2013-12-31 | Nkr12.55 Million | -- |